MMTIF MICROMEM TECHNOLOGIES INC

BULLISH Impact: 6/10 6-K
Horizon months Filed Mar 30, 2026 Processed 2mo ago SEC 0001062993-26-001694
Notable filing: 6-K
Latest settled — T+20d
MMTIF ▼ -15.00% at T+20d
LONG call ✗ call lost -15.00% · α vs SPY -24.42% · entry $0.0200 → $0.0170
Next anchor: T+60d in 15d
Currently $0.0140 · -30.00% from $0.0200 entry
Entry anchored
Mar 30, 2026
via day open
T+1d
+50.00%
call +50.00% · α +49.25%
$0.0300
settled 2mo ago
T+5d
+50.00%
call +50.00% · α +46.06%
$0.0300
settled 2mo ago
T+20d
-15.00%
call -15.00% · α -24.42%
$0.0170
settled 6w ago
T+60d
call — · α —
in 15d

Price Chart

Loading chart...

Executive Summary

Micromem Technologies Inc. announced a technical milestone in its liquid-phase sensor development, successfully detecting clinically relevant biomarkers like TREM-1 with high sensitivity. This advancement supports progression to the next phase of development and expands the technology's potential into commercial medical diagnostics, particularly point-of-care testing.

Actionable Insight

While this is a technical milestone rather than a commercial breakthrough, the expansion into medical diagnostics significantly broadens the company's addressable market. Traders should monitor for future validation studies, regulatory pathway announcements, or partnership developments that could translate this technical success into commercial traction.

Key Facts

  • Company demonstrated successful detection of key biomarkers (Angiopoietin-1, Streptavidin, TREM-1) using its NWFET technology
  • TREM-1 was detected at low concentration levels, confirming high sensitivity of the platform
  • Near-term next steps include further biomarker validation and completion of microfluidic integration
  • Technology has dual-use potential in both defense (biochemical threat detection) and commercial medical diagnostics
  • Filing is a 6-K containing a press release with no financial data or material agreements

Financial Impact

No immediate financial impact disclosed; potential long-term value enhancement from expanded market opportunities in medical diagnostics

revenuemarket opportunitytechnology valuation

Risk Factors

  • Technology is still in development phase with no guaranteed commercialization
  • No timeline provided for market entry or regulatory approval
  • Company has significant derivative liabilities and convertible debt as shown in recent 20-F filing

Market Snapshot

Exchange
OTC
Sector
Services-Computer Programming Services

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001062993-26-001694
Document: form6k.htm0001062993-26-001694
Document: 0001062993-26-001694-index-headers.html0001062993-26-001694
Document: 0001062993-26-001694-index.html0001062993-26-001694
Document: 0001062993-26-001694.txt0001062993-26-001694
4 reports for MMTIF
Performance horizon
Filters
Rows
Reports for MMTIF — sortable, filterable
Type Now
Jun 1, 2026
8d ago
6-K
NEUTRAL ★ 3/10
$0.0100 $0.0100· 0.00%▲ +0.72%$0.0140 (+40.00%)
May 19, 2026
21d ago
6-K
NEUTRAL ★ 3/10
$0.0200 $0.0200· 0.00%▼ −0.19%$0.0140 (−30.00%)
May 11, 2026
29d ago
6-K
NEUTRAL ★ 2/10
$0.0200 $0.0200· 0.00%▼ −0.54%$0.0140 (−30.00%)
Mar 30, 2026
10w ago
6-K
BULLISH ★ 6/10
$0.0200 $0.0300▲ +50.00%▲ +49.25%$0.0140 (−30.00%)
Showing 4 of 4

US Market Status

Market Closed — Opens Thu (11h 18m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access